Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
A phase 2 trial of Olaparib and Durvalumab in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Overview
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer is a phase 2 interventional study registered as NCT05498155 by AstraZeneca, with 50 participants enrolled, started 2022-11-07 and due to reach its primary completion in 2024-11-20. Interventions recorded: Neoadjuvant Olaparib monotherapy group and Neoadjuvant combination therapy with olaparib plus durvalumab.
Similar pages
not linked directly; found by shared links- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Olaparib, Durvalumab, AstraZeneca and the tag pipeline.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares Olaparib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSafety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSavolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Shares Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialEIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Shares Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.